The Readout Loud

336 Episodes

1. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

   Published: 11/21/2024
2. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

   Published: 11/14/2024
3. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

   Published: 11/7/2024
4. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

   Published: 10/31/2024
5. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

   Published: 10/24/2024
6. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

   Published: 10/17/2024
7. 326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

   Published: 10/10/2024
8. 325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

   Published: 10/3/2024
9. From Tradeoffs: Race to the Bottom

   Published: 9/28/2024
10. 324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

    Published: 9/26/2024
11. 323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

    Published: 9/19/2024
12. 322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

    Published: 9/12/2024
13. 321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

    Published: 9/5/2024
14. 320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

    Published: 8/29/2024
15. From "Say More": What Happens When AI Decides Your Medical Coverage

    Published: 8/23/2024
16. 319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

    Published: 8/22/2024
17. 318: Drug pricing drops & psychedelics under fire

    Published: 8/15/2024
18. 317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

    Published: 8/8/2024
19. 316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

    Published: 8/1/2024
20. 315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves

    Published: 7/25/2024